INTRODUCTION
Mitochondrial permeabilization and cytochrome c (Cyt c) release are key events that trigger caspase activation and apoptosis in mammalian cells (1) . Mitochondrial release of Cyt c has been considered the point of commitment to death for most mitotic cells (2, 3) . However, postmitotic cells, such as neurons, can restrict apoptosis even after Cyt c release, enabling recovery from mitochondrial damage and survival (4) . Apoptosis is suppressed in neurons by the inhibition of proapoptotic caspases by Xlinked inhibitor of apoptosis protein (XIAP) and by the maintenance of a reducing cellular environment that prevents the oxidation of Cyt c, thereby restricting its proapoptotic activity (5, 6) . Sympathetic neurons, for example, can recover from mitochondrial permeabilization if caspase activation is restricted (7, 8) . Several factors regulate Cyt c-mediated caspase activation. For example, physiological levels of potassium (9) , nucleotides (10) , and transfer RNA (11) can inhibit apoptosome formation, and various proteins including the tumor suppressor PHAPI, TUCAN (tumor-up-regulated CARD-containing antagonist of caspase-9), and the caspase inhibitor Aven can inhibit apoptosome-mediated caspase activation (12) . In contrast, the proapoptotic activity of Cyt c is enhanced by oxidation (13) and nitrosylation (14) .
Apoptosis inhibition is also a fundamental hallmark of cancer cells (15) , which appear to have adapted to suppress apoptosis after the release of Cyt c (3, 4, 12) . Like neurons, many cancer cells are resistant to cytosolic Cyt c (6) , and both neurons and cancer cells use glucose extensively and engage the pentose phosphate pathway to generate a reducing cellular environment that limits the ability of Cyt c to activate caspases and induce apoptosis (6) . These findings have revealed the possibility that the multiple mechanisms that have evolved in neurons to restrict apoptosis may be adopted by transformed mitotic cells during cancer development and progression.
Although neurons and cancer cells are known to restrict apoptosis and survive mitochondrial permeabilization, what happens to Cyt c after its release from mitochondria is not clear. Here, we investigated the fate of cytosolic Cyt c after its release from mitochondria in situations where apoptosis is restricted.
RESULTS

Cytosolic Cyt c is targeted for proteasome-mediated degradation in neurons
To examine what happens to cytosolic Cyt c that is released from the mitochondria in cells that do not then undergo apoptosis, we injected sympathetic neurons from newborn mice and mouse embryonic fibroblasts (MEFs) with truncated BH3-interacting domain death agonist (tBID), which induces mitochondrial permeabilization, in the presence of a caspase inhibitor. As expected, after its release from mitochondria, Cyt c accumulated in the cytosol of fibroblasts. In neurons, however, Cyt c released from the mitochondria was comparably undetectable (Fig. 1A) , suggesting that cytosolic Cyt c was targeted for degradation in neurons. Absence of cytosolic Cyt c was also observed in neurons when Cyt c release was induced by nerve growth factor (NGF) deprivation (Fig. 1B and fig. S1A ) (16) . Addition of the proteasome inhibitors lactacystin or bortezomib resulted in the accumulation of Cyt c in the cytosol (Fig. 1, B to D, and fig. S1B ), suggesting that Cyt c degradation was proteasome-dependent. Given that Cyt c release induces apoptosis, we hypothesized that this degradation of cytosolic Cyt c may be an important mechanism for neuronal survival because it would allow neurons to withstand mitochondrial damage and suppress apoptosis caused by the release of Cyt c.
Low Apaf-1 abundance is a key determining factor for Cyt c degradation
We next examined whether the apparent degradation of Cyt c was also seen in other postmitotic cells. We found that mouse cardiomyocytes and myotubes also exhibited rapid reduction in the abundance of cytosolic Cyt c after its release from mitochondria was induced with tBID ( fig. S1C ). To examine whether cellular differentiation into a postmitotic state engages the pathway of Cyt c degradation, we used the rat pheochromocytoma PC12 cells, which either can be maintained in a mitotic, undifferentiated state or can be differentiated into neuronal-like cells in response to the addition of NGF (17, 18) . Undifferentiated or differentiated PC12 cells were treated with staurosporine to induce the release of Cyt c from mitochondria, and Cyt c presence was assessed by immunofluorescence. In contrast to the accumulation of Cyt c in the cytosol seen in undifferentiated PC12 cells, cytosolic Cyt c was markedly decreased in the differentiated PC12 cells (Fig. 2, A and  B) . The abundance of mitochondrial-released cytosolic Cyt c was also less in differentiated than in undifferentiated, mitotic PC12 cells in response to a different apoptotic stimulus, the DNA-damaging agent etoposide (Fig.  2B) , suggesting that degradation of Cyt c was not stimulus-specific.
To gain insight into the mechanism by which neuronal differentiation engages the pathway for Cyt c degradation, we focused on the key components of the apoptosome, which is formed as mitochondrial-released Cyt c binds to apoptotic protease-activating factor 1 (APAF-1) to promote caspase-9 and caspase-3 activation and results in cell death (1) . We found that the abundance of Apaf-1 was reduced in mouse neurons and differentiated rat PC12 cells, whereas caspase-9 and caspase-3 abundance appeared to be unchanged ( Fig. 2C) (18) . Apaf-1 abundance was also reduced in postmitotic mouse cardiomyocytes and myotubes (19, 20) . We hypothesized that low Apaf-1 could render cytosolic Cyt c vulnerable to targeting for degradation. Therefore, we tested whether Apaf-1 deficiency could confer the ability to degrade cytosolic Cyt c on mitotic cells. As predicted, staurosporine-induced release of mitochondrial Cyt c in wild-type MEFs resulted in the accumulation of Cyt c in the cytosol. In marked contrast, Apaf-1 knockout MEFs treated with staurosporine had reduced abundance of Cyt c in the cytosol, and this was inhibited by the proteasome inhibitor N-carbobenzyloxy-L-leucyl-L-leucyl-L-leucinal (MG132) (Fig. 2, D and E, and fig. S2 , A and B), suggesting that this degradation was mediated by the proteasome pathway. Subcellular fractionation of these cells also showed less mitochondrially released cytosolic Cyt c after staurosporine treatment and its accumulation in the cytosol in the presence of the proteasome inhibitor MG132 (Fig. 2F) . These results reveal that the mechanism targeting cytosolic Cyt c for degradation is not unique to postmitotic cells and show that mitochondrially released cytosolic Cyt c that is unable to bind Apaf-1 is targeted for degradation by the proteasome.
Because proteasome degradation is mediated by ubiquitin, we examined the ubiquitination of Cyt c using Apaf-1 knockout MEFs expressing hemagglutinin (HA)-tagged ubiquitin and Flag-tagged Cyt c. Robust ubiquitination of mitochondrially mitochondrial-released Cyt c was detected in cells treated with staurosporine in the presence of proteasome inhibitors ( Fig. 2G and fig. S2C ). To rule out the possibility that the higher molecular weight bands were from Cyt c-associated proteins rather than Cyt c itself, the protein mixture was first heated in the presence of 1% SDS to disassociate proteinprotein interactions before being subjected to immunoprecipitation. These high molecular weight bands were detected even under denaturing conditions (Fig. 2G ), confirming that they corresponded to ubiquitinated Cyt c.
Neuroblastoma and glioblastoma cells degrade cytosolic Cyt c
Our previous studies show that the antiapoptotic mechanisms engaged by neurons to ensure their long-term survival have been adopted by many cancer cells to evade apoptosis (4, 6) . Thus, degrading Cyt c could allow cancer cells to survive apoptotic stresses that induce mitochondrial damage. In response to various apoptotic stimuli, including staurosporine, DNA damage by etoposide, and g-irradiation, Cyt c was released from mitochondria and markedly decreased unless cotreated with a proteasome inhibitor in both glioblastoma (U-87 MG, herein called U87-MG) and neuroblastoma (SH-SY5Y) cell lines (Fig. 3, A to D) . The abundance of mitochondrially released cytosolic Cyt c was also stabilized when U87-MG cells were transfected with small interfering RNA (siRNA) against ubiquitin (Fig. 3B ), suggesting that in cancer cells, as in neurons, cytosolic Cyt c is degraded by the ubiquitin-dependent proteasome pathway.
Cyt c degradation is mediated by the E3 ligase PARC/CUL9
To identify the specific E3 ligase that ubiquitinates cytosolic Cyt c, we performed a screen of an siRNA library of human E3 ligases (table S1 ). U87-MG cells were reversetransfected with pools of four siRNAs against each target gene. After incubation for 3 days to allow for target gene silencing, cells were treated with staurosporine (in the presence of a caspase inhibitor) to induce the release of Cyt c. An siRNA against ubiquitin, which blocked the assumed degradation of Cyt c ( . After the primary screen and secondary validation (using three independent, nonpooled siRNAs), we identified p53-associated Parkin-like cytoplasmic protein [PARC, also known as cullin-9 (CUL9) and herein referred to as PARC/CUL9] as the only E3 ligase that prevented Cyt c accumulation in the cytosol in this assay; its knockdown increased the amount of detectable Cyt c in the cytosol ( Fig. 4A and fig. S3B ). PARC/CUL9 belongs to the cullin family of E3 ligases (21, 22) and has substantial homology with the C terminus of Parkin (22), an E3 ligase that is mutated in Parkinson's disease ( Fig. 4B) (23, 24) . Whereas Parkin targets damaged mitochondria for degradation through mitophagy (25) , the substrates of PARC/CUL9 are not yet known. We examined whether cytosolic Cyt c interacted with PARC/CUL9 in cells upon mitochondrial permeabilization. U87-MG cells were treated with staurosporine in the presence of proteasome inhibitor, and PARC/CUL9 was then immunoprecipitated from cytosolic fractions and probed for Cyt c. Our results showed that Cyt c and PARC/CUL9 formed a complex upon mitochondrial permeabilization in these cells (Fig. 4C) . Ubiquitination of Cyt c was markedly reduced in U87-MG cells that were stably knocked down for PARC/CUL9 (Fig. 4D ). In vitro, recombinant Cyt c was ubiquitinated by endogenous PARC/CUL9 immunoprecipitated from U87-MG (Fig. 4E ), together indicating that PARC/CUL9 ubiquitinates Cyt c. We next examined whether this ubiquitination by PARC/CUL9 mediated the degradation of cytosolic Cyt c in the multiple cell types in which decreased abundance of mitochondrial-released cytosolic Cyt c was observed. In U87-MG cells, short hairpin RNA (shRNA)-mediated knockdown of PARC/CUL9 increased the cytosolic accumulation of Cyt c in response to staurosporine ( fig. S3C ), as did siRNA-mediated knockdown of Parc/Cul9 in Apaf-1 knockout MEFs ( fig. S3D ). Sympathetic neurons from newborn mice were microinjected with either a scrambled control or a Parc/Cul9-targeted siRNA and then deprived of NGF to induce the release of Cyt c. Whereas neurons injected with control siRNA showed markedly decreased cytosolic abundance of mitochondrial-released Cyt c, neurons deficient in Parc/Cul9 had increased accumulation of Cyt c in the cytosol (Fig. 5A) . Together, the data suggest that the ubiquitination of Cyt c by PARC/CUL9 promotes its degradation.
PARC/CUL9 promotes cell survival after mitochondrial damage
Because PARC/CUL9 was identified as the E3 ligase targeting Cyt c, we investigated whether PARC/CUL9 was more abundant in cells that lacked cytosolic Cyt c upon its release. Parc/Cul9 was markedly more abundant in mouse neurons and differentiated PC12 cells (which lacked cytosolic accumulation of Cyt c) compared with fibroblasts and undifferentiated PC12 cells (which did exhibit cytosolic Cyt c) (Fig. 5B) . PARC/CUL9 abundance in U87-MG cells was similar to that in normal human CCL151 fibroblasts, whereas APAF-1 abundance was lower ( fig.  S4A ). Thus, although basal PARC/CUL9 abundance in the context of low APAF-1 abundance appears to be sufficient for cytosolic Cyt c degradation, neuronal differentiation may be accompanied not only by a decrease in APAF-1 (Fig. 2C ) but also by a marked increase in PARC/CUL9.
Next, we examined whether overexpression of PARC/CUL9 could promote survival in cells that were exposed to mitochondrial damage. We focused on cells that did not exhibit endogenous degradation of mitochondrially released Cyt c, inferred from a lack of cytosolic accumulation. HeLa cells and wildtype MEFs were treated with the Bax activator compound Bam7 (26) or the mitochondrial uncoupler carbonyl cyanide p-trifluoromethoxyphenylhydrazone (FCCP) to induce mitochondrial damage and release Cyt c. We found that overexpression of PARC/CUL9 prevented cytosolic accumulation of Cyt c in a significantly increased proportion of cells compared with those overexpressing vector alone (Fig. 5C ). PARC/ CUL9 overexpression also conferred significant protection from cell death in response to mitochondrial damage in HeLa cells ( S4C ). Given these results, we predicted that Parc/Cul9 deficiency would make neurons more vulnerable to mitochondrial damage. We obtained sympathetic neurons from Parc/Cul9-deficient mice (27) and cultured them with various agents that induce mitochondrial damage. We found that Parc/Cul9-deficient neurons were more sensitive to mitochondrial damage induced by NGF deprivation, etoposide, or tBID injection compared with wild-type neurons (Fig. 5 , E to G).
To critically determine whether cells expressing PARC/CUL9 are better equipped to recover after mitochondrial damage, we examined long-term survival in both cancer cells and neurons. We focused first on SH-SY5Y neuroblastoma cells and determined the time point after apoptotic treatment at which most cells had undergone mitochondrial outer membrane permeabilization (MOMP), using the Smac (1-60) mCherry construct as an indicator (28) (Fig. 6A) . We found that most cells had released Smac to the cytosol after 3 hours of staurosporine treatment (Fig. 6B) , and knockdown or overexpression of PARC/CUL9 had no effect on the release of Smac from mitochondria ( Fig. 6B and fig. S4 , D and E), indicating that the kinetics of MOMP were not affected by PARC/CUL9. SH-SY5Y cultures transduced with control shRNA had a significantly higher amount of cells 5 days after staurosporine treatment compared to those that were transduced with PARC/CUL9 shRNA, as assessed by a methylene blue absorbance assay (Fig. 6C) , suggesting that PARC/CUL9 activity conferred a proliferative or survival advantage on cancer cells. To examine the importance of Parc/Cul9 on long-term survival after mitochondrial damage in neurons, we isolated sympathetic neurons from wild-type and Parc/Cul9 knockout mice. Both sets of neurons were deprived of NGF for 18 hours, a period that was previously shown to induce MOMP in these cells (8) , and then cultured in medium restored with NGF for seven additional days (Fig. 6D) . At 4 days after NGF restoration, both neuron cultures exhibited partially degenerated cell bodies. However, after 7 days, wild-type neurons were clearly identifiable with large and phasebright cell bodies and exhibited increased survival compared with Parc/ Cul9-deficient neurons, which were atrophic and appeared degenerated (Fig. 6 , E and F), indicating that Parc/Cul9 deficiency impaired neuronal recovery after mitochondrial damage. Together, these results show that PARC/CUL9 ubiquitinates Cyt c for degradation in neurons and cancer cells in response to mitochondrial damage, thereby degrading the mitochondrially released Cyt c and suppressing cell death.
DISCUSSION
Despite the central role of Cyt c in activating apoptosis, the mechanism by which Cyt c itself is regulated in cells is poorly understood. The mitochondrial release of Cyt c has been considered to be the point of no return in the apoptotic cascade because of the mitochondrial damage incurred as a consequence of mitochondrial permeabilization occurring before Cyt c release in cells (3) . Thus, a cell could die of mitochondrial dysfunction and energetic failure even if caspase activation is blocked. However, sympathetic neurons have been shown to maintain survival and recover even after mitochondrial permeabilization and Cyt c release (7, 8) . Our results here show that neurons that have released Cyt c but are unable to activate caspases engage a mechanism to rapidly degrade Cyt c and eliminate any further risk of activating the apoptotic machinery.
A question that emerged was whether the ability to degrade Cyt c was particular to postmitotic cells such as neurons or whether the degradation machinery was present in all cells but selectively engaged in postmitotic cells. Our results show that a key feature common to multiple postmitotic cells where Cyt c degradation was observed was that these cells had low levels of Apaf-1. Because Apaf-1 is the main protein that Cyt c binds to upon its release from mitochondria, low Apaf-1 levels could leave an excess of Cyt c available for degradation. Also, because the interaction between Apaf-1 and Cyt c is thought to be transient (29) , all cytosolic Cyt c could become available for degradation if apoptosis is unable to proceed. Our results show that Apaf-1 deficiency alone can confer the ability of degrading Cyt c on mitotic cells such as fibroblasts that otherwise do not degrade cytosolic Cyt c. These results are significant because they imply that the machinery that targets cytosolic Cyt c for degradation is not unique to postmitotic cells. Indeed, Apaf-1-deficient neural precursor cells have also been shown to degrade Cyt c (30, 31) . Together, these results point to Apaf-1 as a key factor that determines whether Cyt c remains stable in the cytosol or is targeted for degradation once it is released from the mitochondria.
Using an unbiased siRNA screen, we identified PARC/CUL9 as an E3 ligase that targets Cyt c, once released from the mitochondria, for degradation. Whereas PARC/CUL9 has been identified as an E3 ligase on the basis of the presence of RING and cullin domains (22, 27, 32) , our results identify Cyt c as its first known substrate. Because Cyt c degradation occurs only after its release from mitochondria, any previous proteomic approach to identify the PARC/CUL9 substrates would have failed to detect Cyt c because it would have remained in the mitochondria under normal conditions. Our data show that PARC/CUL9 could ubiquitinate Cyt c in vitro, and its knockdown increased the accumulation of cytosolic Cyt c in cells. However, a fraction of cells still degraded Cyt c even in the absence of PARC/CUL9, indicating that an alternative E3 ligase could also target Cyt c for degradation.
The C terminus of PARC/CUL9 is highly similar to Parkin, a known E3 ligase with mutations that are associated with Parkinson's disease (24) . Parkin is well known to be recruited to damaged mitochondria and promote their degradation (25) . The high degree of structural similarity that we observed between PARC/CUL9 and Parkin suggests that, like Parkin, PARC/CUL9 may also be important for promoting neuronal survival after mitochondria injury. Consistent with this model, our results showed that Parc-Cul9-deficient neurons were more vulnerable to multiple situations of mitochondrial damage. PARC/CUL9 overexpression was also sufficient to degrade cytosolic Cyt c and promote survival in mitotic cells exposed to mitochondrial damage. We also examined the ability of PARC/CUL9 to regulate neuronal recovery after mitochondrial damage by conducting a long-term survival assay. Indeed, our results showed that PARC/CUL9-deficient neurons were less capable of recovery after mitochondrial damage and rescue (Fig. 6) . Although PARC/ CUL9 can reduce the risk of apoptosis by targeting mitochondrially released Cyt c for degradation and promoting neuronal recovery, it is important to point out that sympathetic neurons with substantially dysfunctional mitochondria cannot be maintained alive indefinitely. These neurons are remarkably capable of maintaining mitochondrial membrane potential despite the loss of Cyt c for a period, in part by maintaining adenosine triphosphate (ATP) generation through glycolysis (8, 33, 34) . Our results reiterate the notion that sympathetic neurons are not irreversibly committed to die upon mitochondrial permeabilization and that PARC/CUL9 is important for optimal neuronal rescue during this time.
As in neurons, the ability to evade apoptosis is one of the hallmarks of cancer cells (15) . In previous reports, we identified the strict inhibition of caspases by XIAP and the reducing cellular environment as two mechanisms by which apoptosis is selectively restricted in neurons as well as cancer cells (4, 6) . Neurons and cancer cells have also been shown to recover from mitochondrial permeabilization if apoptosis is restricted (7, 8, 28) . We found that cytosolic Cyt c appeared to be degraded in cancer cells just as is observed in neurons, indicating that these cells engage redundant mechanisms to ensure survival in situations of mitochondrial damage. Degradation of cytosolic Cyt c could also be important even if apoptosis is inhibited, because persistent accumulation of cytosolic Cyt c over a long period could be detrimental to cells. For example, although the binding of Cyt c to APAF-1 at the WD40 domain has been well studied (35) (36) (37) , it is conceivable that Cyt c may also interact with other WD40 domain-containing proteins with negative consequences. The mechanism by which Cyt c is degraded in both neurons and cancer cells involved proteasomal targeting of Cyt c by the same E3 ligase, PARC/CUL9. An important implication of these results is that even though neurons and cancer cells are markedly different cell types, they are strikingly similar with regard to apoptosis restriction and that the survival mechanisms evolved by neurons may be co-opted by cancer cells to evade apoptosis.
MATERIALS AND METHODS
Reagents
Lactacystin, MG132, bortezomib, and leupeptin were purchased from Boston Biochem. Ammonium chloride, FCCP, etoposide, and staurosporine were purchased from Sigma. The cell-permeable Bax inhibitor Bam7 was provided by L. Walensky (Harvard Medical School) as a lyophilized powder that was resuspended in DMSO (10 mM stocks). Propidium iodide and SYTOX Green were purchased from Invitrogen.
Cell culture
MEFs, HeLa cells, human embryonic kidney (HEK) 293T cells, and CCL151 fibroblasts were cultured in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum (FBS) (Sigma). U87-MG and SH-SY5Y cell lines were purchased from the American Type Culture Collection (ATCC) and cultured in RPMI 1640 supplemented with 10% FBS (Sigma), 1% nonessential amino acids, and 1% sodium pyruvate (Gibco). Undifferentiated PC12 cells (provided by R. Pittman, University of Pennsylvania, Philadelphia) were cultured in DMEM and Ham's F-12 Nutrient Mixture (DMEM/F12) supplemented with 10% FBS, 10% heat-inactivated horse serum (Sigma), and glucose (4500 mg/liter; Fisher). For differentiation, cells were grown in the presence of NGF (50 ng/ml; Harlan) for 8 to 10 days before experiments were performed. Primary cardiomyocyte cultures were isolated from P0-P1 mice using the Worthington Neonatal Cardiomyocyte Isolation System (Worthington Biochemical Corp.) according to the manufacturer's instructions. A pre-plating step (for 2 hours) was included to reduce the number of fibroblasts in the cultures. Cells were then plated on laminincoated plates in minimal essential medium with Earle's salt supplemented with 2 mM glutamine (Gibco), 10% horse serum, 5% FBS, penicillin (100 mg/ml; Gibco), and streptomycin (100 mg/ml; Sigma). Experiments were performed on cells 6 to 8 days after plating. Satellite cell-derived primary myoblasts were isolated from adult lower hindlimb muscle from neonates to 1-month-old mice, and supplemented with basic fibroblast growth factor (2.5 ng/ml; Invitrogen). The primary cultures were maintained on collagen-coated dishes in Ham's F10 supplemented with 20% FBS, penicillin (200 U/ml), streptomycin (200 mg/ml), and 0.002% Fungizone (Invitrogen). The medium was changed every other day, and cultures were differentiated with the addition of differentiation medium when they reached 60 to 70% confluency. All experiments were performed with primary cultures that had undergone between 4 and 12 passages. All experiments were performed after 14 days of differentiation.
Sympathetic neuronal cultures
For isolation of wild-type neurons, ICR/CD1 outbred mice (Harlan) were used. All knockout mice were on a C57BL/6 background, and wild-type littermates served as controls. Primary sympathetic neurons were dissected from the superior cervical ganglia of postnatal day 0 and day 1 mice (P0-P1). Cells were plated on collagen-coated dishes at a density of 60,000 cells per well for Western blotting, or 10,000 cells per well for microinjection, viability, or immunofluorescence experiments. Sympathetic neurons were grown for 4 to 5 days in NGF-containing medium before being treated with experimental conditions. For treatments, etoposide (Sigma) was used at a concentration of 20 mM. For NGF deprivation, cultures were rinsed three times with medium lacking NGF, followed by the addition of a neutralizing antibody against NGF raised in goat to this medium in the presence of caspase inhibitors QVD-OPH or z-VAD-FMK (SM Biochemicals).
For the assessment of cell viability, sympathetic neurons were grown in NGF-containing medium (AM50) for 4 to 5 days, and then either maintained in AM50 or treated with various conditions. For NGF deprivation, cultures were rinsed twice with AM50 medium lacking NGF (AM0), followed by the addition of AM0 containing an antibody against NGF raised in goat to deplete residual NGF. For rescue experiments in which NGF was added to NGF-deprived cultures, cultures were rinsed three times and incubated in NGF-containing medium (AM50) for seven additional days. Seven days after NGF addition, rescued neuron cultures were identifiable by large and phase-bright cell bodies, whereas nonrescued neuron cultures appeared atrophic and degenerated.
XIAP-or PARC/CUL9-deficient neurons were isolated from XIAP or PARC/CUL9 knockout C57BL/6 mice, respectively, and neurons from wild-type littermate were used as controls. Apaf-1-deficient MEFs were isolated from Apaf-1 -/-C57BL/6 mice, and fibroblasts from wild-type littermates were used as controls. Apaf-1 -/-mice were generated by J. Herz (University of Texas Southwestern Medical Center) and were provided by S. Ackerman (The Jackson Laboratory).
RNA interference screen and cell transfections
To identify the specific E3 ligase that targets cytosolic Cyt c for degradation, we screened an siRNA library of human E3 ligases from Dharmacon (RefSeq database v5.0-8.0; table S1). All transfections were performed with siGENOME SMART pools (four siRNAs per gene; 50 nM final concentration). Each well contained pools of four siRNAs that targeted individual genes, and six wells per target gene (for three untreated and three treated conditions) were plated with 5000 cells per well on each 96-well plate. Each 96-well plate was analyzed in triplicate for a total of nine independent untreated and nine independent treated experiments. Each plate also contained cells transfected with a scrambled siRNA as a negative control or siRNA against ubiquitin as a positive control (again, six wells per plate, in triplicates). U87-MG cells were reverse-transfected with the siRNAs, and after a period of 3 days to enable silencing of target genes, cells were either left untreated or treated with staurosporine (for 24 hours) to induce the release of Cyt c. The status of Cyt c was then assessed by immunofluorescence to identify potential E3 ligases that, when decreased in abundance, caused the cytosolic accumulation of mitochondrial-released Cyt c. An siRNA against ubiquitin (Dharmacon), which appeared to block the degradation of Cyt c (in the presence of caspase inhibitors) and caused cell death (in the absence of caspase inhibitors) (Fig. 4A) , was included as a positive control in the screen. Reverse transfections were performed by mixing appropriate Dharmafect (Thermo Fisher Scientific) with siRNA pools and incubating for 20 min, followed by delivery of single-cell suspensions derived from trypsin digestion. After the primary screen, a secondary validation was performed with three independent (not pooled) siRNAs (Sigma), using the same assay to determine the status of cytosolic Cyt c.
For targeted siRNA and overexpression experiments, cells were cultured overnight in DMEM supplemented with 10% FBS. Transfections were performed using Lipofectamine 2000 (Invitrogen) in accordance with the manufacturer's instructions. For PARC/CUL9 overexpression, we used the pCDNA3-HA-PARC plasmid 20937 (Addgene). The Smac (1-60) mCherry construct was provided by D. R. Green (St. Jude Children's Research Hospital). For shRNA transductions, we used five Escherichia coli clones expressing pLKO1-shRNA Cul9 plasmids (Open Biosystems). Lentiviruses were produced in HEK293T cells (ATCC) by transfection using each of the pLKO1-shRNA Cul9, pCMV DR 8.76, and pMD2G plasmids by the Lenti-shRNA Core Facility at the University of North Carolina. Lentiviruses used to transduce U87-MG, SH-SY5Y, and Apaf-1 cells were added to cells in 1:3 dilution of stock lentivirus in cell medium for 16 hours. Cells were then cultured for 24 hours in complete medium, and then stable clones expressing the shRNA against PARC/CUL9 were selected using puromycin (5 to 10 mg/ml). To select the best shRNA clone against PARC/CUL9, samples were then analyzed by Western blotting, and the best clone was used to determine the effects of PARC/CUL9 knockdown in stabilizing Cyt c.
Immunofluorescence
The status of Cyt c (whether in the mitochondria or released) was examined by immunostaining with an antibody against Cyt c. Briefly, sympathetic neurons were cultured for 4 days, after which they were either left untreated or deprived of NGF for various time points. Neurons and other cell lines were fixed in 4% paraformaldehyde and incubated overnight with an antibody against Cyt c (556432, BD Biosciences) followed by a 2-hour incubation with anti-mouse Cy3 secondary antibody (The Jackson Laboratory). Nuclei were stained with Hoechst 33258 (Molecular Probes).
Microinjection
The method of microinjecting sympathetic neurons was described previously (6, 38) . After injections, the number of viable cells injected was determined by counting rhodamine-positive cells that had intact phase-bright bodies. The nucleus was injected with tBid plasmid (200 ng/ml) or siRNA (50 nM) and an enhanced GFP (EGFP)-expressing DNA (50 ng/ml; Clontech Laboratories Inc.) in microinjection buffer. After allowing 24 hours for expression, GFP-expressing cells were identified by fluorescence microscopy. The survival of these double-injected cells was assessed by morphological criteria (39) . For injection of siRNA, neurons were dissected from P2 mice, cultured for 3 days, and then microinjected with siRNA to PARC/CUL9 or scrambled control in the presence of rhodamine (Sigma). For experiments in which neuronal survival was assessed in response to mitochondrial damage, neurons were deprived of NGF in the presence of cycloheximide for 48 hours (to relieve XIAP-mediated inhibition of caspases) (5, 16) before being microinjected with tBID peptide (8 mM; AnaSpec) for 10 hours. To assess cell survival, the cell-impermeable dyes propidium iodide and SYTOX Green (Molecular Probes) were added to cells at final concentrations of 1 mg/ml and 10 nM, respectively, and incubated at 37°C in the dark for 20 min. Cell death was quantitated by counting apoptotic nuclei (condensed or fragmented) stained with Hoechst staining solution and by SYTOX Green and propidium iodide dye exclusion.
Image acquisition and processing
Immunofluorescence images were acquired by an ORCA-ER digital B/W charge-coupled device camera (Hamamatsu) mounted on a DMIRE2 inverted fluorescence microscope (Leica), using MetaMorph version 7.6 software (Molecular Devices). For most quantification experiments, 300 cells were analyzed in triplicate, independent samples. The data presented in the figures show the mean percentage of apoptosis ± SEM of three independent experiments. In the case of the siRNA screen, a high-content imaging scope (ArrayScan VTI HCS Reader, Thermo Scientific) was used to take 18 images of each well in a 96-well plate format, using a 20×/0.8 numerical aperture objective. Confocal images were taken on an Olympus FV1000 confocal microscope.
Ubiquitination assays
Cells were transfected with 2 mg of Flag-tagged Cyt c and HA-tagged ubiquitin constructs. Cells were treated 24 hours later with staurosporine in the presence or absence of MG132 (Boston Biochem) for 16 hours. Cells were then lysed in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitor cocktail (see immunoprecipitation methods) and 1 mM Nethylmaleimide (Sigma-Aldrich). For denaturing conditions, cells were lysed in 1% SDS and boiled for 10 min. Samples were then diluted with 0.5% NP-40 and subjected to immunoprecipitation. Total protein (1 mg) was incubated with EZview Red ANTI-FLAG M2 Affinity Gel (SigmaAldrich) overnight. After stringent washes, samples were suspended in 30 µl of Laemmli sample buffer containing 2% (v/v) b-mercaptoethanol and boiled for 5 min. Subsequent Western blotting analysis was performed using horseradish peroxidase (HRP)-conjugated antibodies against Flag and HA to avoid cross-reaction with immunoglobulin (Roche).
For the in vitro ubiquitination assays, PARC/CUL9 was immunoprecipitated from U87-MG cells and washed five times with high-salt phosphatebuffered saline (PBS) buffer (containing 500 mM NaCl) followed by five washes with PBS. Reaction volumes of 40 ml containing 3.5 mM Mg-ATP (Boston Biochem), 3.5 mM Energy Regeneration solution (Boston Biochem), 40 nM human ubiquitin-activating enzyme, 150 nM HsUbc7, and 500 nM recombinant Cyt c were incubated for 2 hours at 37°C in the presence of 10 mM unlabeled wild-type or mutant ubiquitin (Boston Biochem). Reactions were quenched with 15 µl of Laemmli sample buffer containing 2% (v/v) b-mercaptoethanol and boiled for 5 min. Ubiquitination was detected by Western blotting.
Long-term cell survival assays
Cell survival, assessed as the relative absorbance by cell cultures after various treatments, was determined by fixing and staining cell cultures with methylene blue (Sigma-Aldrich) dissolved in 50% methanol. Color extraction was performed using 0.5 M hydrochloric acid, and staining (which was proportional to cell number) was quantitated by measuring the absorbance at 595 nm on a microplate reader (Biotex ELx808). All experiments were conducted three times, each in duplicate.
Immunoprecipitations
For the detection of PARC complexes, cells were collected by scraping and pelleted at 1000 rpm for 10 min at 4°C. Cell pellets were then lysed in 200 µl of ice-cold 1% Triton in PBS containing protease inhibitors [protease inhibitor cocktail (Sigma-Aldrich P8340), 1 mM phenylmethylsulfonyl fluoride]. After preclearing 200 µl of the sample with 20 µl of protein G-Sepharose at 4°C for 1 hour, immunoprecipitation was performed by incubating 200 µl of the lysates with 2 to 4 µg of a polyclonal antibody against PARC (Bethyl Laboratories) at 4°C for 2 hours. Immunocomplexes were precipitated with 20 µl of protein G-Sepharose. After three washes with 1000 µl of 1% Triton buffer, beads were boiled in 30 µl of Laemmli buffer, and 15 µl of the eluted proteins was analyzed by Western blotting. Immunoprecipitation with mouse immunoglobulin G (IgG) was used as a negative control.
Western blot analysis
Cultured cells were lysed in RIPA buffer. Protein concentrations were quantified using the bicinchoninic acid method (Thermo Scientific, 23227), and equal concentrations of protein were resolved on SDS-polyacrylamide gels and then transferred onto polyvinylidene difluoride membranes. Immunologic analysis was performed on a SNAP ID device (Millipore) according to the manufacturer's protocol with primary antibodies. We used antibodies against mouse Apaf-1 (13F11; Alexis Biochemicals), XIAP (R&D Systems), b-actin (Sigma-Aldrich), Cyt c (BD Biosciences), caspase-9 (Cell Signaling Technology), caspase-3 (Cell Signaling Technology), Flag or HA tags (HRP-conjugated, Sigma-Aldrich), heat shock protein 70 (Cell Signaling Technology), and PARC (Bethyl Laboratories and Santa Cruz Biotechnology). HRP-conjugated secondary antibodies against mouse or rabbit IgG were purchased from Pierce Chemical Co. Western blots were developed with ECL Plus reagent (Amersham Biosciences).
Subcellular fractionation
The mitochondrial and cytosolic fractions were prepared using an Apo-Alert cell fractionation kit from BD Biosciences Clontech. Equal amounts of protein were loaded for Western blot analysis with Cyt c and LDH.
Statistical analysis
P values for the differences between means were calculated with an unpaired, two-tailed Student's t test.
SUPPLEMENTARY MATERIALS
www.sciencesignaling.org/cgi/content/full/7/334/ra67/DC1 Fig. S1 . Degradation of mitochondrially released Cyt c in neurons, cardiomyocytes, and myotubes. Fig. S2 . Cyt c ubiquitination and degradation in Apaf-1-deficient cells. Fig. S3 . Inhibition of Cyt c degradation in PARC/CUL9-deficient cells. Fig. S4 . PARC/CUL9 overexpression inhibits cell death after MOMP. Table S1 . List of genes included in the siRNA library of human E3 ligases from Dharmacon.
